Micrographia Bio is a pioneering applied AI-first life sciences company with a mission to deliver a new era of drug discovery through spatial proteomics.

Current drug discovery methods such as genomics & transcriptomics have failed at cost-effective drug discovery. Micrographia Bio was founded on the belief that the future of drug discovery will be driven by spatial proteomics: the understanding of protein-protein networks inside cells that will ultimately determine mechanisms of action of medicines.

At Micrographia Bio, we dive deep into visualising proteins in their spatial context. We are building world class solutions to radically improve the probability of success in drug discovery. We are advancing internal pipeline therapeutic candidates focused on fundamental cellular pathways.